Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers

@article{Sekar2008DarunavirRitonavirPF,
  title={Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers},
  author={V. Sekar and S. Spinosa-Guzman and E. Paepe and M. Pauw and T. Vangeneugden and E. Lefebvre and R. Hoetelmans},
  journal={The Journal of Clinical Pharmacology},
  year={2008},
  volume={48}
}
This study investigated the steady‐state pharmacokinetic interaction between the HIV protease inhibitor, darunavir (TMC114), administered with low‐dose ritonavir (darunavir/ritonavir), and clarithromycin in HIV‐negative healthy volunteers. In a 3‐way crossover study, 18 individuals received darunavir/ritonavir 400/100 mg bid, clarithromycin 500 mg bid, and darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid in 3 separate sessions for 7 days, with a washout period of at least 7… Expand
19 Citations
Darunavir: an effective protease inhibitor for HIV-infected patients
  • 5
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
  • 20
  • PDF
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
  • 76
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers
  • 35
  • PDF
Clinical Pharmacokinetics of Clarithromycin
  • 169
Pharmacokinetic interaction between ritonavir and clarithromycin *
  • 72
The management of HIV-1 protease inhibitor pharmacokinetic interactions.
  • 50
  • PDF
...
1
2
3
...